Welcome to our dedicated page for Lemaitre Vasculr SEC filings (Ticker: LMAT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for LeMaitre Vascular, Inc. (NASDAQ: LMAT), a Delaware-incorporated medical device company focused on vascular devices, implants, and services for peripheral vascular disease. Through these filings, investors can review the company’s formal disclosures on operations, financial condition, risk factors, and governance.
LeMaitre’s SEC submissions include annual reports on Form 10-K and quarterly reports on Form 10-Q, which present detailed financial statements, segment information, and discussions of risks such as competition, supplier dependence, regulatory compliance for devices and tissue products, international operations, product defects or recalls, litigation, and intellectual property protection. Current reports on Form 8-K, such as those referenced in the provided materials, disclose events like quarterly financial results, board decisions, and other material developments.
The company also uses its filings to describe capital markets activities, including the listing of its common stock on The Nasdaq Global Market under the symbol LMAT, the existence of convertible senior notes, dividend declarations, and share repurchase authorizations. These documents complement the non-GAAP metrics discussed in press releases by providing reconciliations and additional context for measures such as organic sales growth, adjusted margins, and EBITDA.
On Stock Titan, LeMaitre’s filings are updated in near real time from the SEC’s EDGAR system. AI-powered summaries help explain the key points in lengthy documents like 10-Ks and 10-Qs, highlight important changes from prior periods, and clarify the implications of 8-K disclosures. Users can also review insider-related filings such as Forms 3, 4, and 5, where available, to track transactions by directors and officers. This combination of raw filings and AI-generated insights allows readers to understand LMAT’s regulatory record and financial reporting more efficiently.
LeMaitre Vascular, Inc. (LMAT) filed a Form 144 proposing the sale of 976 common shares through Morgan Stanley Smith Barney LLC on 08/12/2025 on NASDAQ, with an aggregate market value of $90,553.28. The notice indicates 22,637,522 shares outstanding, so the position is a very small fraction of the company.
The 976 shares were acquired from the issuer as a mix of restricted stock and performance shares across five lots on dates in December 2024 and March 8, 2025 (198, 205, 201, 171, and 201 shares, which total 976). The filer reports no securities sold in the past three months and certifies they have no undisclosed material adverse information about the issuer.
LeMaitre Vascular (LMAT) filed a Form 144 reporting a proposed sale of 6,561 common shares through Morgan Stanley Smith Barney LLC on the NASDAQ with an aggregate market value of $607,229.74. The filing lists 22,637,522 shares outstanding and an approximate sale date of 08/11/2025. The securities were acquired by a stock option exercise on 08/11/2025 with payment in cash.
The filing also discloses a recent sale by JOHN ADAM ROUSH of 939 shares on 08/08/2025 for $87,784.39. The notice includes the standard representation that the seller is not aware of any undisclosed material adverse information about the issuer.
LeMaitre Vascular (LMAT) filed a Form 144 reporting a proposed sale of 10,815 common shares on NASDAQ with an aggregate market value of $999,173.07. The form states these shares equal roughly 0.048% of the 22,637,522 shares outstanding. The securities were acquired and are being sold on 08/11/2025 through a stock option exercise, with payment in cash, and the sale is to be executed through Morgan Stanley Smith Barney LLC. The filing notes no securities sold in the past three months by the selling person and includes the filer’s representation that they are unaware of any undisclosed material adverse information.
LeMaitre Vascular insider sale summary: George W. LeMaitre, who serves as Chairman and CEO and is a company director, reported a sale of 100,000 shares of LeMaitre Vascular Inc. (LMAT) on 08/06/2025. The sale was executed under a pre-established 10b5-1(c) trading plan adopted on 03/10/2025 and was carried out in multiple trades at a weighted average price of $93.5053, with individual trades ranging from $93.03 to $94.00. After the reported transaction, the reporting person beneficially owned 1,727,003 shares. The filer notes willingness to provide full trade-level details on request. No derivative transactions were reported on this Form 4.
LeMaitre Vascular (LMAT) submitted a Form 144 reporting a proposed sale of 939 shares of common stock with an aggregate market value of $87,784.39. The notice names Morgan Stanley Smith Barney LLC as broker and lists the approximate sale date as 08/08/2025 on NASDAQ, and shows 22,637,522 shares outstanding.
The filing states the securities were acquired on 08/08/2025 by a stock option exercise from the issuer and paid in cash. The section for securities sold in the past three months is marked "Nothing to Report". The form includes the standard attestation that the seller does not possess undisclosed material adverse information and references Rule 144 disclosure requirements.
LeMaitre Vascular, Inc. Form 144 reports a proposed sale of 2,500 common shares on NASDAQ through Morgan Stanley Smith Barney LLC with an aggregate market value of $235,000 and an approximate sale date of 08/08/2025. The filing lists 22,637,522 shares outstanding, showing the reported sale is a very small fraction of the companys outstanding stock.
The securities-to-be-sold were recorded as acquired by a stock option exercise on 08/08/2025 with payment in cash. The filing also discloses a prior sale by Bridget A Ross of 3,750 shares on 05/12/2025 for $312,000. Several filer identification fields (for example Filer CIK and Filer CCC) are not populated in the provided text. The signer affirms no undisclosed material adverse information.
On Form 144, insider George W. LeMaitre filed notice to sell 100,000 common shares of LeMaitre Vascular Inc. (LMAT) through Charles Schwab on or about 6 Aug 2025. At the referenced price, the block is valued at $9.35 million and represents roughly 0.44 % of the 22.64 million shares outstanding.
The filing also lists three prior sales by the same holder between 16–20 May 2025 totaling 100,000 shares for $10.71 million in gross proceeds. The shares being disposed of were originally acquired on 2 Jun 1997 via a promissory-note transaction.
No operational or financial results are provided; the document strictly satisfies Rule 144 disclosure requirements. Nevertheless, the continued insider dispositions may create a modest share-supply overhang and could be interpreted as a signal of profit-taking ahead of the August execution date.